| Literature DB >> 32133003 |
Allison R Rogala1,2, Akihiko Oka2, R Balfour Sartor2,3.
Abstract
When identifying the key immunologic-microbial interactions leading to either mucosal homeostasis in normal hosts or intestinal inflammatory responses in genetically susceptible individuals, it is important to not only identify microbial community correlations but to also define the functional pathways involved. Gnotobiotic rodents are a very effective tool for this purpose as they provide a highly controlled environment in which to identify the function of complex intestinal microbiota, their individual components, and metabolic products. Herein we review specific strategies using gnotobiotic mice to functionally evaluate the role of various intestinal microbiota in host responses. These studies include basic comparisons between host responses in germ-free (GF), specific-pathogen-free or conventionally raised wild-type mice or those with underlying genetic susceptibilities to intestinal inflammation. We also discuss what can be learned from studies in which GF mice are colonized with single wild-type or genetically-modified microbial isolates to examine the functions of individual bacteria and their targeted bacterial genes, or colonized by multiple defined isolates to determine interactions between members of defined consortia. Additionally, we discuss studies to identify functions of complex microbial communities from healthy or diseased human or murine hosts via fecal transplant into GF mice. Finally, we conclude by suggesting ways to improve studies of immune-microbial interactions using gnotobiotic mice.Entities:
Keywords: fecal microbial transplant (FMT); germ-free (GF); gnotobiotic and conventional mice; inflammatory bowel disease (IBD); intestinal inflammation; microbiota; mucosal homeostasis
Mesh:
Year: 2020 PMID: 32133003 PMCID: PMC7040030 DOI: 10.3389/fimmu.2020.00214
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Clinically relevant questions that can be answered by gnotobiotic studies.
| 1. | Is dysbiosis the cause or consequence of intestinal immune-mediated inflammation/obesity/metabolic syndrome? |
| 2. | What accounts for individual outcomes in disease course and response to therapies? |
| 3. | Can manipulation of microbial composition or function alter disease activity or outcomes? |
Strategies to functionally analyze microbial constituents, genes, and metabolites in gnotobiotic mice.
| Complex resident microbiota | GF vs. SPF, SPF, or human FMT → GF |
| Active components of complex microbial groups | Progressive deconvolution, functional screening |
| Defined consortia (intra- and trans-kingdom) | Colonize GF—groups of deconvoluted strains |
| Single strains | Monoassociation compared with GF or SPF |
| Functional genes | Monoassociate isogenic strains: wild-type and deletion, transgenic, complemented mutants |
| Metabolic pathways | Substrate availability, isogenic gene deletion, provide agonist to GF mice, antagonists, host receptor mutants. |
GF, germ-free; SPF, specific pathogen-free; FMT, fecal microbial transplant.
Figure 1A conceptual framework for the influences of an individual's resident microbiota on mucosal immune responses. The diverse microbiota and their metabolic products are selectively sampled by the intact mucosa of a healthy host to activate regulatory immune responses that mediate homeostasis. In contrast, the dysbiotic microbiota and their immunologically active components leak through the permeable mucosa of a genetically susceptible host to stimulate unrestrained aggressive effector immune responses that cause inflammation and tissue injury. IL, interleukin; TLR, Toll-like receptor; MLN, mesenteric lymph node; Mϕ, macrophage; DC, dendritic cell; ILC3, innate lymphoid cell 3; iNKT, invariant natural killer T cell; CD, cluster of differentiation; IEL, intraepithelial lymphocyte; SCFA, short chain fatty acids; Ig, immunoglobulin; IFN, interferon; TNF, tumor necrosis factor; MMP, matrix metalloprotease; iTreg, inducible T regulatory; TGF, transforming growth factor; TH, T helper; TR1, T regulatory 1.
Balance of protective and potentially aggressive resident intestinal bacteria and metabolites.
| Bacteroides species ( | Enterobacteriaceae ( |
| Clostridium species (select members of groups IV, XIVa, XVIII) | |
| Lachnospiraceae | |
| Fusobacterium species ( | |
| Lactobacillus species ( | |
| SCFA (butyrate, propionate, pentenoate) | ↓SCFA |
| Indoles | Hydrogen sulfide |
| Sphingolipids | Sulfated bile acids |
| Secondary bile acids | Primary bile acids |
| Ethanolamine | |
| Iron | |
Strategies to improve translation of gnotobiotic murine model results to human application.
| 1. Use clinically relevant human microbial strains for selective colonization |
| 2. Collect specimens from donors with important clinical disease phenotypes and matched healthy controls for FMT → “humanized” ex-GF mice |
| 3. Validate results in at least two separate recipient GF strains or different inflammatory models, preferably with different mechanism of disease induction |
| 4. For therapeutic studies, use treatment as well as preventive protocols |
| 5. Cautiously interpret results |